Ind-Swift Laboratories shareholding pattern

·Pharma & Health Chart ›

Who owns itSep 2026 quarter

Promoters42.93%no change

Foreign investors (FII)10.78%−0.12 pts

Domestic institutions (DII)0.20%+0.05 pts

of which mutual funds0.00%no change

of which insurance companies0.00%

Public46.09%

Per cent of all shares; change on the Sep 2026 quarter, in percentage points. As filed with the exchanges.

Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

alphave

INDSWFTLAB₹378.95

Ind-Swift Laboratories Limited

· Pharma & Health

₹ CrorePeersSMSPHARMA SOLARA DCAL HIKAL UNICHEMLAB GUFICBIO PANACEABIO RPGLIFEMcap ₹3,291 Cr

Holding % of Total Shares 12 Months Ending	Q3 FY25 31/12/2024	Q4 FY25 18/03/2025	Q4 FY25 31/03/2025	Q1 FY26 30/06/2025	Q2 FY26 30/09/2025	Q3 FY26 31/12/2025	Q4 FY26 31/03/2026	Q1 FY27 30/06/2026	Q2 FY27 17/09/2026	Q2 FY27 30/09/2026
Promoter & Group	42.00	40.94	40.94	40.94	39.50	39.50	42.99	42.93	42.93	42.93
FII / FPI	0.46	3.00	3.07	4.27	14.80	14.33	13.88	10.70	10.90	10.78
DII	0.94	0.91	0.91	0.91	0.68	0.68	0.00	0.17	0.15	0.20

Latest: 2026-09-30 · 29 quarters of history · click a row to chart it.

« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave

Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.